"/>

国产精品99一区二区三_免费中文日韩_国产在线精品一区二区_日本成人手机在线

FDA approves two drugs combined to treat aggressive thyroid cancer

Source: Xinhua    2018-05-05 03:21:12

WASHINGTON, May 4 (Xinhua) -- The U.S. Food and Drug Administration (FDA) approved on Friday new uses for two drugs administered together for the treatment of a kind of anaplastic thyroid cancer (ATC).

Tafinlar (dabrafenib) and Mekinist (trametinib) in combination have been greenlighted to treat ATC that cannot be removed by surgery or has spread to other parts of the body and has a type of abnormal gene called BRAF V600E.

"This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and the third cancer with this specific gene mutation that this drug combination has been approved to treat," said Richard Pazdur, director of the FDA's Oncology Center of Excellence.

"This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients."

Both drugs have been approved for use, alone or in combination, to treat BRAF V600 mutation-positive metastatic melanoma.

Also, Tafinlar and Mekinist are approved for use, in combination, to treat BRAF V600E mutation-positive, metastatic non-small cell lung cancer.

Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid gland.

Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer, accounting for about 1 to two percent of all thyroid cancers.

The trial measured the percent of patients with a complete or partial reduction in tumor size, according to FDA.

Of 23 evaluable patients, 57 percent experienced a partial response and four percent experienced a complete response.

In nine (64 percent) of the 14 patients with responses, there were no significant tumor growths for six months or longer.

Both Tafinlar and Mekinist can cause harm to a developing fetus, so women should be advised of the potential risk to the fetus and to use effective contraception, FDA warned.

Editor: Chengcheng
Related News
Xinhuanet

FDA approves two drugs combined to treat aggressive thyroid cancer

Source: Xinhua 2018-05-05 03:21:12

WASHINGTON, May 4 (Xinhua) -- The U.S. Food and Drug Administration (FDA) approved on Friday new uses for two drugs administered together for the treatment of a kind of anaplastic thyroid cancer (ATC).

Tafinlar (dabrafenib) and Mekinist (trametinib) in combination have been greenlighted to treat ATC that cannot be removed by surgery or has spread to other parts of the body and has a type of abnormal gene called BRAF V600E.

"This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and the third cancer with this specific gene mutation that this drug combination has been approved to treat," said Richard Pazdur, director of the FDA's Oncology Center of Excellence.

"This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients."

Both drugs have been approved for use, alone or in combination, to treat BRAF V600 mutation-positive metastatic melanoma.

Also, Tafinlar and Mekinist are approved for use, in combination, to treat BRAF V600E mutation-positive, metastatic non-small cell lung cancer.

Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid gland.

Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer, accounting for about 1 to two percent of all thyroid cancers.

The trial measured the percent of patients with a complete or partial reduction in tumor size, according to FDA.

Of 23 evaluable patients, 57 percent experienced a partial response and four percent experienced a complete response.

In nine (64 percent) of the 14 patients with responses, there were no significant tumor growths for six months or longer.

Both Tafinlar and Mekinist can cause harm to a developing fetus, so women should be advised of the potential risk to the fetus and to use effective contraception, FDA warned.

[Editor: huaxia]
010020070750000000000000011100001371567761
主站蜘蛛池模板: 丰都县| 潮州市| 双峰县| 蒙城县| 诸暨市| 汶川县| 岑巩县| 渝中区| 聂荣县| 德惠市| 西宁市| 江阴市| 西畴县| 集安市| 定南县| 两当县| 赤城县| 苏州市| 英超| 涿鹿县| 五常市| 凉城县| 利辛县| 库车县| 宁南县| 丽江市| 荃湾区| 横山县| 城固县| 诸城市| 五大连池市| 峨眉山市| 嘉善县| 阿瓦提县| 隆昌县| 河曲县| 东乡族自治县| 宣城市| 吴川市| 汽车| 舞阳县|